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systemic lupus erythematosus (SLE). Kidney biopsy is an invasive procedure and accompanied
by potential risks. Thus deﬁning a reliable biomarker of kidney involvement in SLE is highly desir-
able.
Aim of the work: To assess the role of anti-C1q Ab in combination with anti-dsDNA Ab in
detection of SLE disease activity and renal involvement (lupus nephritis).
Patients and methods: Anti-C1q Ab and anti-dsDNA antibodies were determined in 60
randomly selected adult SLE patients one of them refused the biopsy and those who completed
the study were 59. The control group included 25 age and sex matched volunteers. According to411901.
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204 A. El-Hewala et al.lupus nephritis (LN) and SLEDAI score, patients were divided into four groups: group 1, 11
patients had active disease with LN; group 2, 20 patients had inactive disease with LN; Group3,
six patients had active disease without LN; group 4, 22 patients had inactive disease without LN.
Results: A signiﬁcant association of active lupus nephritis detection and the presence of either
one or both of the studied antibodies (anti-C1q Ab or anti-dsDNA). None of the patients of group
1 had anti-C1q Ab only, and none was negative for anti-C1q Ab and anti-dsDNA Ab together.
Levels of anti-C1q Ab and anti-dsDNA Ab were signiﬁcantly higher in more active LN than less
active LN. Anti-dsDNA and anti-C1q antibodies sensitivity and speciﬁcity for detection of more
active LN was 85.0% and 64.0% and 70.0% and 55.0%, respectively, and 75.0% and 91.0% for
both. Both antibodies had a positive correlation with SLEDAI score and proteinuria and a negative
correlation with C3 reduction. A high signiﬁcant positive correlation was detected between anti-C1q
Ab and anti-dsDNA Ab.
Conclusion: Anti-C1q Ab, in combination with anti-dsDNA Ab may serve as potential reliable
and none invasive markers of SLE disease activity and renal involvement to avoid unnecessary renal
biopsies.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Glomerulonephritis is one of the commonest and most serious
manifestations of (SLE). Renal involvement in SLE carries sig-
niﬁcant morbidity and mortality [1]. Early diagnosis and rapid
treatment of lupus nephritis are crucial to improve survival in
SLE patients [2].
The complement system plays an important role in the
onset as well as throughout the course of SLE. The disease is
most often associated with autoantibodies against C1q (anti-
C1q), the ﬁrst component of the classical pathway of comple-
ment [3].
A major pathogenic hypothesis is that SLE involves defec-
tive renal clearance of immune complexes, and consumption of
the early components of the classical complement pathway,
such as C1q, C3, and C4, which are strongly associated with
the development of active SLE [4]. A Low C1q level is related
to the presence of anti-C1q-antibodies with the formation of
C1q/anti-C1q immune complexes with subsequent develop-
ment of glomerulonephritis [5]. Anti-C1q antibodies are pres-
ent in 20–44% of patients with SLE in cross-sectional studies
and are associated with the presence of nephritis [1].
This study was done to assess the role of anti-C1q Ab in
combination with anti-dsDNA Ab in detection of SLE disease
activity and renal involvement (lupus nephritis).
2. Patients and methods
2.1. Study subjects and design
The current study was observational cross sectional study.
Sample was estimated to be 60 adults SLE patients (53 females
and 7 males) by using total number of patient available in
1 year 150 cases and the expected percentage of positive C1q
Ab in lupus nephritis 50% and the power of our study was
80% with conﬁdence interval 95%. Sample was collected by
systematic random method. The study was done in the period
from September 2009 to September 2010. Patients ages ranged
from 21 and 49 years of mean ± SD (38.1 ± 7.8), disease
duration ranged between 2.5 and 4 years of mean ± SD/
months (36.4 ± 10.4). Twenty-ﬁve (22 females and 3 males)apparently healthy volunteers (from those attending the
hospital for donation of blood) were included as controls, they
were age and sex matched with the patients, their ages
mean ± SD/years were (37.7 ± 8.8).
SLE patients fulﬁlled at least four criteria of SLE according
to American College of Rheumatology [6]. SLE disease activity
was based on the SLEDAI score amended in 2000 [7], patients
with a score 64 were considered inactive while those with a
score >4 were considered active.
The Systemic Lupus International Collaborating Clinics
(SLICC) Damage Index, which has been endorsed by the
American College of Rheumatology, was also used [8].
All patients were collected from Rheumatology and Reha-
bilitation and Internal Medicine Departments in Zagazig Uni-
versity Hospitals, Sharkia governorate, Egypt which is the
only hospital in Sharkia governorate that had a speciﬁc inter-
nal medicine nephrology department that deals with renal
biopsy for diagnosis and management of lupus nephritis.
Thirty-two out of the 59 patients were diagnosed as lupus
nephritis according to ACR criteria: proteinuria P500 mg/
day and/or red cell casts [6]. The diagnosis of renal involve-
ment was conﬁrmed in 31 of them by renal biopsy as one
patient refused to do biopsy, so excluded from the study.
According to renal involvement (LN) and SLEDAI score,
patients were divided into four groups: group 1, 11 patients
had active disease with LN; group 2, 20 patients had inactive
disease with LN; group3, six patients had active disease
without LN; group 4, 22 patients had inactive disease without
LN.
The biopsies classiﬁed according to The International Soci-
ety of Nephrology/Renal Pathology Society, classes III and IV
are considered more active, while classes I, II, and V are
considered less active [9]. Five patients were in class II. The
majority of patients were in classes III and IV (12 and 8
patients, respectively); six patients were in class V. None of
the 31 patients was in class I.
Lupus treatment, at the time of serum sampling, involved
low-dose prednisolone (<0.5 mg/kg/day) in thirty patients,
high-dose prednisolone (P0.5 mg/kg/day) in 28 patients, inter-
mittent intravenous cyclophosphamide in nineteen patients,
oral azathioprine in 45 patients.
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hepatitis or HIV infection.
Ethical consideration: A written consent was taken from all
of the participants after explaining details, beneﬁts as well as
risks to them. Only one of LN patients refused to do renal
biopsy and so was not included in the study.
2.2. Laboratory procedures
All serum samples were collected in the morning after 9 h fast-
ing. Laboratory investigations were done for all subjects
including:
- Complete blood count (CBC), Erythrocyte sedimentation
rate (ESR), urine analysis: to detect proteinuria, micro-
scopic examination for pus cells, red blood cells, and casts
as indications of renal affection quantitative 24 h urinary
protein excretion (turbidity assay).
- Complement C-3 by cobas integra 400 (turbidimetric assay).
- Antinuclear antibody (ANA) was done with the indirect
immunoﬂorescence technique using (Hep-2 substrate,
IMMCO Diagnostics, Inc., USA.
- Anti-dsDNA Ab were also determined by EIA (the Binding
Site, Birmingham, UK). Positive ﬁndings for anti-dsDNA
Ab were deﬁned at levels >30 IU/ml.
- IgG anti-C1q antibodies were measured in serum using a
commercially available enzyme-linked immunosorbent
assay kit (Bu¨hlmann Laboratories, Scho¨nenbuch, Switzer-
land). In this assay, undigested puriﬁed human C1q
served as antigen, and sera were diluted and incubated
in a high-salt buffer (1 M NaCl) in order to prevent
the binding of immune complexes. In the last step, after
adding the enzyme substrate tetramethylbenzidine (TMB)
to the wells. The reaction is terminated by the addition
of stop solution. The optical densities were measured at
450 nm converted into units (U/ml) by being plotted
against the autoantibody concentration of the standards
given by the manufacturer. To deﬁne our cut-off levelsTable 1 Demographic, clinical and laboratory data of SLE patient
SLE with LN (N
Sex
Female n.% 27 (87%)
Male n.% 4 (13%)
Age/years (mean ± SD) 38.0 ± 7.2
Anti-C1q Ab (U/ml) 151.6 ± 14.12*
Anti-dsDNA (U/ml) 293 ± 51*
C3 (g/l) 0.37 ± 0.2*
* Signiﬁcant when comparing SLE with LN versus without LN.
Table 2 Clinical and laboratory parameters in SLE patients accord
Active SLE (n
Anti-C1q-Ab (U/ml) 141.26 ± 54.2
Anti-dsDNA (U/ml) 285 ± 20*
C3 (g/l) 0.47 ± 0.13
SLEDAI 10.26 ± 3.11
* Signiﬁcant difference comparing active versus inactive SLE patients.of abnormal result, Anti-C1q Ab was measured in 25
healthy controls. Based on these investigations, we calcu-
lated an optimized cutoff value at the 98th percentile
(that is, 30 U/ml).
Statistics: The collected data were statistically analyzed
using SPSS version 11.0 (SPSS Inc., Chicago, IL, USA), com-
parison between group means was done using the Mann–Whit-
ney U test while chi-squared test and ﬁsher exact tests were
used for qualitative data. For correlation analysis, Spearman’s
correlation coefﬁcient was used. Odd’s ratio and conﬁdence
interval were also calculated. The signiﬁcance level was consid-
ered at P value <0.05.
3. Results
3.1. Comparison between SLE patients according to the presence
and absence of lupus nephritis
The only signiﬁcant difference was detected comparing the
selected laboratory data of patients groups versus the control
group (Table 1).
3.2. Comparison between SLE patients as regard SLEDAI
SLEDAI recorded signiﬁcantly higher scores in active than
inactive patients. Also there was signiﬁcant difference in levels
of anti-C1q Ab, anti-dsDNA Ab, and C3 reduction in active
than in inactive patients (Table 2).
3.3. Comparing groups 1 versus 2 regarding anti-C1q Ab and
anti-dsDNA Ab
Fig. 1 shows signiﬁcant elevation of anti-C1q Ab and anti-
dsDNA Ab serum levels in group 1 (LN with active SLE) than
group 2 (LN with inactive SLE).s according lupus nephritis, irrespective to SLEDAI.
o. = 31) SLE without LN (No. = 28)
25 (89%)
3 (11%)
39.0 ± 6.2
146.3 ± 15.7
280 ± 69
0.39 ± 0. 3
ing to SLEDAI, irrespective to renal affection.
= 17) Inactive SLE (n= 42)
2* 66.3 ± 13.22
65 ± 15
* 0.67 ± 0.14
* 3.01 ± 1.0
Figure 1 Comparing group 1 versus 2 regarding anti-C1q Ab
and anti-dsDNA Ab.
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antibodies
Presence of anti-C1q Ab, anti-dsDNA Ab, and both of them
was signiﬁcantly associated with LN in active patients. None
of group1 patients had anti-C1q Ab only, and none was nega-
tive for both anti-dsDNA Ab and anti-C1q Ab (Table 3).
3.5. Comparison between levels of studied antibodies as regard
renal biopsy grades
Regarding renal biopsy grades, anti-C1q Ab as well as anti-
dsDNA Ab levels were signiﬁcantly higher in more active
LN (biopsy grades III and IV together) than less active LN
(biopsy grades II and V together) P< 0.05 (Fig 2).
3.6. Signiﬁcant predictors of studied antibodies
For detection of more active lupus nephritis among the biopsy
proven LN patients, sensitivity and speciﬁcity for anti-dsDNA
Ab was 85.0% and 64.0%, for anti-C1q Ab was 70.0% and
55.0%, and 75.0% and 91.0% for both antibodies. Detection
of both anti-C1q Ab and anti-dsDNA Ab could predict 94%
of those more active LN and exclude 67% of those who had
lower activity of LN proven by biopsy (Table 4).Table 3 Comparison between group 1 versus group 2 as well as ot
+ve LN patients (No. = 31)
Active SLE
(No. = 11) group 1
Inactive SLE
(No. = 20) gr
Anti-dsDNA Ab +ve (n= 37) 11 (100%)*,+ 10 (50%)
Anti-C1q Ab +ve (n= 31) 9 (82%)*,+ 10 (50%)
Anti-C1q Ab +ve and anti-
dsDNA +ve (n= 24)
9 (82%)*,+ 7 (35%)
Anti-C1q Ab +ve and anti-
dsDNA ve (n= 8)
0 (0.00%)*,+ 4 (19%)
Anti-C1q Ab ve and anti-
dsDNA +ve (n= 14)
3 (27.30%) 5 (27.0%)
Anti-C1q Ab ve and anti-
dsDNA ve (n= 17)
0 (0.00%)*,+ 7 (37.0%)
+ve, positive or present; ve, negative or absent.
* Signiﬁcant when comparing group 1 or 2 versus groups 3 and 4.
+ Signiﬁcant when comparing group 1 versus 2.3.7. Correlation between anti-C1q-Ab and different laboratory
and clinical parameters
Serum levels of anti-C1q Ab and anti-dsDNA Ab showed a
signiﬁcant positive correlation with SLEDAI, proteinuria.
High signiﬁcant correlation was found between anti-C1q Ab
and anti-dsDNA Ab (P< 0.001), they had signiﬁcant negative
correlations with C3 levels (P< 0.05) (Table 5).4. Discussion
Renal involvement is one of the main determinants of poor
prognosis of SLE [10]. Kidney biopsy is the golden standard
diagnostic tool for the assessment of renal involvement in
SLE, however it is invasive procedure and accompanied by
potential risks moreover, serial evaluations are sometimes
needed but cannot routinely be performed due to the invasive
nature [11]. Thus deﬁning an early and reliable and non
invasive biomarker of kidney involvement in SLE is highly
desirable [12].
Patients with LN irrespective to SLEDAI in the present
study showed non signiﬁcant differences from those without
LN regarding serum levels of anti-C1q Ab, anti-dsDNA Ab
as well as complement reduction, this data was in agreement
with another two studies [13–15].
In the present study, the increase in SLEDAI scores, anti-
C1q Ab, anti-ds DNA Ab as well as the reduction of C3 levels
was more signiﬁcant in active patients than inactive patients
irrespective of renal affection. Similar to our ﬁndings, three
other studies found signiﬁcantly higher titers of anti-C1qAb
in patients with active disease compared with those with
inactive SLE [14,16,17], also Bernstein et al. [18] reported
signiﬁcantly higher serum levels of anti-dsDNA Ab in the ac-
tive than in the inactive SLE patients.
We found signiﬁcant associations and higher titers of anti-
C1q Ab, as well as anti-dsDNA Ab when comparing group 1
versus 2, also a signiﬁcant high detection of these antibodies in
patients of group 1 comparing it with groups 3 and 4; that
support the indirect role for these antibodies in the pathogen-
esis of lupus nephritis. Moroni et al. detected a signiﬁcant asso-her patients groups (3&4) regarding the studied antibodies.
ve LN (No. = 28) OR (CI)
oup 2
OR (CI) Groups 3 and 4
8.36 (1.13–77.4) 16 (57%) 6.95 (1.06–57.8)
10.5 (1.38–100.7) 12 (42%) 9.5 (1.4–80.9)
8.0 (1.19–62.5) 8 (30%) 6.67 (1.15–43.5)
0.0 (0.0–0.2) 4 (13%) 0.0 (0.0–2.34)
0.7 (0.1–4.46) 6 (20%) 1.13 (0.17–6.8)
0.0 (0.0–1.2) 10 (37%) 0.0 (0.0–3.0)
Figure 2 Comparison between levels of studied antibodies as
regard renal biopsy grades.
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in active SLE-patients with nephritis [19], And Matrat et al.
conﬁrmed that: the presence of anti-C1q and anti-dsDNA
aAbs was associated with a high risk of renal ﬂare, whereas
the absence of both Abs excluded such an event [20].
Evidence from another study found higher titers of anti-
C1q in patients with lupus nephritis also they detected C1q
deposition in the kidney tissue [21]. This observation was
explained by inhibition of removal of apoptotic cells secondary
to complement deﬁciency induced by these antibodies; they
block the clearance of C1q-containing immune complexes,
allowing them to deposit in the glomeruli, or they activate
the complement cascade and consequently the inﬂammatory
process [22].
None of the patients with LN and active SLE (group1) in
the current study had anti-C1q Ab only, and none was nega-
tive for both anti-dsDNA Ab and anti-C1q Ab, which is in
agreement with another study which reported that anti-C1q
antibodies were found in 100% of patients with lupus nephritis
and anti-dsDNA antibodies were found in 93.3% of those
patients [5].
There is a general agreement in different literatures that the
more active classes of biopsy proven LN are classes III and IV,
while other classes, namely classes I, II, V, and VI are consid-
ered less active that needs limited immunosuppressive therapyTable 4 Sensitivity, speciﬁcity for studied antibodies among the LN
Auto antibodies More active LN
(No. = 20)
Less active
(No. = 11
Anti dsDNA (n= 21) 17 4
Anti-C1q Ab (n= 19) 14 5
+ve (Anti dsDNA and
C1qAb) (n= 16)
15 1
More active LN, biopsy grades III and IV; Less active LN, biopsy grade
Sens., sensitivity; Spec., speciﬁcity;+ve: positive or present; ve, negativ
Table 5 Correlation between anti-C1q-Ab and different laboratory
Anti-C1q Ab Anti-dsDNA A
Anti-C1q Ab – 0.69*
Anti-dsDNA Ab 0.69* –
* Signiﬁcant when P< 0.05.[23]. In the present study, anti-C1q Ab as well as anti-dsDNA
Ab levels were signiﬁcantly higher in more active LN (biopsy
grades III and IV together) than less active LN (biopsy grades
II and V together). This goes hand in hand with study done by
Fang et al. who found strong positive association between
anti-C1q and the detection of proliferative lupus nephritis [24].
In the current study, for detection of more active LN
among the biopsy proven LN patients, sensitivity and speciﬁc-
ity for anti-dsDNA Ab was 85.0% and 64.0%, for anti-C1q
Ab was 70.0% and 55.0%, and 75.0% and 91.0% for both
antibodies. Detection of both anti-C1q Ab and anti-dsDNA
Ab could predict 94% of those more active LN and exclude
67% of those who had lower activity of LN proven by biopsy.
Trendelenburg et al. reported that, for the detection of an
active glomerulonephritis in SLE patients, the anti-C1q assay
showed a particularly high sensitivity (97.2%) while speciﬁcity
was 70.3%. [3].
Concurrent with two other studies [22,25], serum levels of
anti-C1q Ab and anti-dsDNA Ab in our study showed a signif-
icant positive correlation with SLEDAI scores and proteinuria
while they had a signiﬁcant negative correlation with C3 levels
and a signiﬁcant correlation was found between anti-C1q Ab
and anti-dsDNA Ab. These suggested that the detection of
anti-C1q antibodies is a potential reliable marker for disease
activity, particularly in the renal site [25].
In conclusion, Anti-C1q-antibodies in combination with
anti-dsDNA-antibodies have high speciﬁcity and sensitivity
in detection of SLE disease activity and renal involvement.
So together, they may serve as potential reliable and none
invasive markers to avoid unnecessary renal biopsies. Both
antibodies are recommended to be assessed for follow up
and monitoring of LN and SLE activity.Scope of the article
Renal involvement is one of the main determinants of poor
prognosis of systemic lupus erythematosus (SLE). Kidney
biopsy is an invasive procedure and accompanied by potentialpatients.
LN
)
Sens.
(%)
Spec.
(%)
+ve predictive
value (%)
ve predictive
value (%)
85 64 81 70
70 55 74 50
75 91 94 67
s II and V).
e or absent.
and clinical parameters.
b C3 SLEDAI Proteinuria
0.32* 0.26* 0.25*
0.58* 0.24* 0.24*
208 A. El-Hewala et al.risks. So, the aim of the current study was assessment of the
role of anti-C1q Ab in combination with anti-dsDNA Ab in
detection of SLE disease activity and renal involvement (lupus
nephritis) and we found they may serve as potential
reliable and none invasive markers to avoid unnecessary renal
biopsies.
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